Cytokine-associated ROS and Ca2+ dysregulation in severe inflammatory cardiomyopathy.

Authors

Phillip Suwalski, Ainoosh Golpour, January Weiner, Nicolas Musigk, Felix Balzer, Niklas Giesa, Ali Amr, Joanna Zyla, Peter Ganz, Hafiza Nosheen Saleem, Johannes Trebing, Farbod Sedaghat-Hamedani, Benjamin Meder, Stefan M Gold, Antje Ebert, Dieter Beule, Ulf Landmesser, Bettina Heidecker

Published in

Cardiovascular research. Aug 30, 2026. Epub Aug 30, 2026.

Abstract

Inflammatory cardiomyopathy (iCMP) is a leading cause of heart failure, with limited therapeutic options. Excessive cytokine levels are implicated in adverse outcomes, but their pathomechanism in iCMP is poorly understood. We sought to identify key cytokines involved in severe iCMP and elucidate their potential contribution to cardiomyocyte injury.
Cytokines were analysed in patients with severe biopsy-proven iCMP (n = 63; LVEF ≤ 35%) and validated in a national cohort (n = 425). In vitro experiments examined the effect of the top cytokines observed in severe iCMP with regards to production of reactive oxygen species (ROS) and calcium homeostasis in induced human pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and human aortic endothelial cells (HAECs). Three proteins (COLEC-12, CRIM-1, IL-6) were associated with severe iCMP. In iPSC-CMs, these proteins increased ROS (H2DCFDA assay) and intracellular Ca2+ levels (Fluo-4AM assay), indicating cellular stress. Effects were less pronounced in HAEC. Finally, real-world data from electronic medical records suggested a possible cardioprotective effect of clinically available inhibitors targeting these cytokines, although these findings remain exploratory and require confirmation in controlled studies.
COLEC-12, CRIM-1, and IL-6 are elevated in severe iCMP and induce oxidative stress and calcium dysregulation in cultured cardiomyocytes. These findings highlight their potential as possible future therapeutic targets.
ClinicalTrials.gov Identifier: NCT04265040, NCT02187263.

PMID:
42669063
Bibliographic data and abstract were imported from PubMed on 30 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.